Francis Knuettel II bought PTHS

July 1, 2025 · Form 4 insider transaction

Francis Knuettel II bought 10,000 shares of Pelthos Therapeutics Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as j and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Acquired (buy-side)
Shares
10,000
Price
$0.00
Total value
N/A
Role
SecuritySeries A Convertible Preferred Stock
Transaction codeJ: J
Transaction dateJuly 1, 2025
Filing dateJuly 3, 2025
Shares owned after10,000
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.; Acquired in connection with cancellation of promissory note.; The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.; Francis Knuettel II is the manager of Camden Capital LLC ("Camden") and the co-trustee of the Lara Knuettel Revocable Trust (the "Trust"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

View the original Form 4 on SEC EDGAR